HCM Risk-SCD for Hypertrophic Cardiomyopathy
Estimates 5-year risk of sudden cardiac death (SCD) in hypertrophic cardiomyopathy to guide ICD implantation (ESC 2014 model).
Score interpretation
HCM Risk-SCD < 4%: Low risk. ICD prophylaxis generally not recommended.
→ No ICD indicated. Annual cardiology review. Avoid competitive sport. Lifestyle counselling.
HCM Risk-SCD 4–5.9%: Intermediate risk. ICD may be considered.
→ ICD consideration in individual clinical context. Detailed discussion of risks/benefits with patient. Specialist HCM centre referral.
HCM Risk-SCD ≥ 6%: High risk. ICD implantation recommended (ESC 2014 Class IIa).
→ ICD implantation recommended. Cardiology specialist centre. Genetic counselling.
Interpretation bands for the HCM Risk-SCD. Apply clinical judgement and local guidance.
References
- O'Mahony C et al. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM Risk-SCD). Eur Heart J. 2014;35(30):2010-2020.
Related
Curated clinical cross-links plus same-class fallbacks.
- Lidocaine IV (Cardiac Arrhythmia) · Antiarrhythmic
- Protamine Sulphate (Heparin Reversal) · Heparin Reversal / Cardiac Surgery
- Mavacamten · Cardiac myosin inhibitor
- Prednisolone (Sudden Sensorineural Hearing Loss) · Corticosteroid (systemic — SSNHL treatment)
- Digoxin · Cardiac Glycoside
- Palivizumab · RSV Prophylaxis — Monthly Monoclonal Antibody (High-Risk Infants)
- Acute Heart Failure · ESC 2021 Heart Failure Guidelines; NICE NG106
- NSTEMI / Unstable Angina · ESC 2020 NSTEMI Guidelines; NICE NG185
- New-Onset Atrial Fibrillation · ESC 2020 AF Guidelines; NICE NG196
- Hypertensive Emergency · ESC/ESH 2018 Hypertension Guidelines; NICE NG136
- Bradycardia Management · Resuscitation Council UK ABCDE; ESC 2021 Pacing Guidelines
- Ventricular Tachycardia / Fibrillation · Resuscitation Council UK ACLS; ESC 2022 Ventricular Arrhythmia Guidelines
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.